The antidepressant properties of selective serotonin reuptake inhibitors (SSRI), such as fluoxetine, as well as other classes of antidepressant agents, involve an increase in the synaptic levels of 5-HT in corticolimbic structures. However, SSRIs also increase 5-HT levels at inhibitory 5-HT 1A and 5-HT 1B autoreceptors localized on serotoninergic cell bodies and terminals, respectively, thereby attenuating their postsynaptic effects (Artigas 1995; Gobert et al. 1997a ). The progressive desensitization of these autoreceptors may, therefore, underlie the delay in onset of antidepressant action (Artigas 1995; Artigas et al. 1996) . By mimicking desensitization, blockade of 5-HT 1A and/or 5-HT 1B autoreceptors enhances the increase in 5-HT levels provoked by SSRIs (Artigas et al. 1996; Gobert et al. 1997a; Hjorth and Auerbach 1996) . Correspondingly, blockade of 5-HT 1A autoreceptors by the arylalkylamine, (-)pindolol, may accelerate the antidepressant actions of SSRIs in humans (Artigas et al. 1996; Blier and Bergeron 1995) . However, (-)pindolol's interaction with human 5-HT 1A receptors has not, as yet, been directly characterized (Artigas 1995) , complicating the interpretation of its actions. In this light, the present study examined the efficacy of (-)pindolol at recombinant 5-HT 1A receptors heterologously expressed in a mammalian (CHO) cell line (Newman-Tancredi et al. 1992) . Its actions were compared with those of 5-HT and the selective 5-HT 1A receptor antagonist, WAY 100,135 (Fletcher et al. 1993) , which also potentiates the increase in 5-HT levels provoked by SSRIs in rats (Hjorth and Auerbach 1996) .
METHODS
Affinity at h5-HT 1A receptors (Newman-Tancredi et al. 1992) 
DISCUSSION
The present data show that (-)pindolol interacts with recombinant 5-HT 1A receptors with high affinity (nanomolar K i value) comparable to that of WAY 100,135.
However, in contrast to the endogenous (full) agonist, 5-HT, and the antagonist, WAY 100,135, (-)pindolol elicits a modest (ca. 20%) activation of [ (-)pindolol behaves as a weak partial agonist at CHOh5-HT 1A receptors. These in vitro data at recombinant human 5-HT 1A receptors are consistent with a report of weak partial agonist properties of (-)pindolol at rat 5-HT 1A receptors (De Vivo and Maayani 1990) and results from in vivo studies in humans, where (-)pindolol acted as a weak partial agonist in modulation of core temperature, corticosterone, and prolactin levels (for review, see Meltzer and Maes 1996) .
As discussed elsewhere (Newman-Tancredi et al. 1997) . CHO-h5-HT 1A cell membranes constitute a model of postsynaptic 5-HT 1A receptors, with agonist efficacies that correspond to those observed for agonist activation of hippocampal 5-HT 1A sites (e.g., Odagaki and Fuxe 1995) . In contrast, at presynaptic 5-HT 1A receptors, which display high density and receptor reserve, the efficacy of (-)pindolol may be amplified (Meller et al. 1990) . Indeed, at high doses, (-)pindolol behaves as a partial agonist in several models thought to reflect activation of autoreceptor-mediated activity in animals and, possibly, in humans (Meltzer and Maes 1996; Hjorth and Auerbach 1996) .
Antagonism of postsynaptic 5-HT 1A receptors and an agonist action at 5-HT 1A autoreceptors would be inconsistent with a potentiation of the activity of serotoninergic neurones by (-)pindolol either alone or in combination with SSRIs (Redrobe et al. 1996; Blier et al. 1997 ). However, in dialysis studies in conscious animals, (-)pindolol fails to affect, or actually increases, postsynaptic levels of 5-HT, consistent with antagonist actions at 5-HT 1A autoreceptors (Hjorth and Auerbach 1996) . Further, as mentioned above, (-)pindolol facilitates the influence of SSRIs upon postsynaptic 5-HT levels, whereas the partial agonist, buspirone, inhibits the actions of SSRIs (Gobert et al. 1997b ). In addition, it has been suggested, on the basis of electrophysiological studies, that low doses (2.5 mg PO) of (-)pindolol may preferentially antagonize raphe-localized rather than hippocampal 5-HT 1A receptors in rats (Blier et al. 1997) . Indeed, the induction of corticosterone secretion observed in humans (which may reflect agonist activity at postsynaptic receptors) is seen at high doses of (-)pindolol (30.0 mg PO; Meltzer and Maes 1996) . The present data show that the intrinsic activity of (-)pindolol at human receptors is markedly lower than that of 5-HT, a relationship likely to hold true for both pre-and postsynaptic sites. Thus, even if (-)pindolol itself exerts partial agonist actions at 5-HT 1A autoreceptors, it will reduce their stimulation by endogenous 5-HT. Hence, (-)pindolol may increase the ability of SSRIs to enhance postsynaptic 5-HT levels and, thereby, their antidepressant actions.
In conclusion, the present data, although globally in accordance with the hypothesis that (-)pindolol increases the antidepressant effects of SSRIs by antagonism of 5-HT at inhibitory 5-HT 1A autoreceptors, highlight the need for further investigation. Indeed, (-)pindolol possesses marked affinity at ␤-adrenergic and 5-HT 1B receptors, in addition to weak partial agonist activity at 5-HT 1A receptors. Therefore, clinical studies with selective and "neutral" 5-HT 1A receptor antagonists will be required to confirm that blockade of 5-HT 1A autoreceptors genuinely enhances the therapeutic actions of SSRIs and other antidepressant agents.
